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The aggregation of the microtubule-associated protein tau into paired helical filaments to form neurofibrillary 
tangles constitutes one of the pathological hallmarks of Alzheimer's disease. Tau is post-translationally 
modified by the addition of N-acetyl-D-glucosamine O-linked to several serine and threonine residues 
(O-GlcNAc). Previously, increased O-GlcNAcylation of tau has been shown to block the accumulation of tau 
aggregates within a tauopathy mouse model. Here we show that O-GlcNAc modification of full-length human 
tau impairs the rate and extent of its heparin-induced aggregation without perturbing its activity toward 
microtubule polymerization. O-GlcNAcylation, however, does not impact the “global-fold” of tau as measured 
by a Förster resonance energy transfer assay. Similarly, nuclear magnetic resonance studies demonstrated 
that O-GlcNAcylation only minimally perturbs the local structural and dynamic features of a tau fragment 
(residues 353–408) spanning the last microtubule binding repeat to the major GlcNAc-acceptor Ser400. 
These data indicate that the inhibitory effects of O-GlcNAc on tau aggregation may result from enhanced 
monomer solubility or the destabilization of fibrils or soluble aggregates, rather than by altering the 
conformational properties of the monomeric protein. This work further underscores the potential of targeting 
the O-GlcNAc pathway for potential Alzheimer's disease therapeutics.Introduction
The aggregation of the microtubule-associated
protein tau to form paired helical filaments, which
ultimately give rise to neurofibrillary tangles (NFTs), is
one of the two pathological hallmarks of Alzheimer's
disease (AD). Given that the extent of NFTs correlates
closely with progression of AD, there has been
increasing attention on the molecular processes that
influence the formation of tau aggregates. Under-
standing the processes that contribute to the ability
of tau to form ordered aggregates is a critical step
toward finding ways to block their formation. A basic
nucleation-dependent mechanism, first proposed by
Oosawa and Kasai to describe the kinetic behavior of
actin polymerization [1], has been shown to accurately
model the aggregation of tau [2,3] and other proteinscontributing to neurodegeneration such as amyloid-β
[4], α-synuclein [5], and the prion protein [6]. In the
nucleation-dependent polymerization mechanism,
the rate-limiting step is the formation of a minimal
nucleus composed of a small number of monomers.
This nucleus is then extended during an elongation
phase until eventually the polymer reaches an
equilibrium with respect to the concentration of
monomeric species in solution. In the case of tau, a
conformational change is thought to be a prerequisite
for its aggregation [7,8]. Studies aimed at character-
izing the structural properties of tau and the effects of
tau post-translational modifications could therefore
provide critical insights into the processes regulating
fibril formation.
One post-translational modification that has been
proposed as a driving force for tau fibril formation is
serine and threonine phosphorylation, which is
generally accepted as preceding its fibrillization
in vivo [9]. Tau, however, is also subject to a number
of other post-translational modifications including,
for example, proteolysis [10–12], acetylation [13],
glycation [14,15], and O-glycosylation by O-linked
N-acetyl-D-glucosamine (O-GlcNAc) [16]. The for-
mation of O-GlcNAc involves the attachment of
GlcNAc to the hydroxyl group of serine and threonine
residues, and this modification is found on a diverse
array of nucleocytoplasmic proteins. The addition
of O-GlcNAc to proteins is catalyzed by a single
glycosyltransferase, O-GlcNAc transferase (OGT)
[17,18]. Similarly, its removal is catalyzed by a single
glycoside hydrolase, O-GlcNAcase (OGA) [19,20].
The dynamic nature of O-GlcNAcylation, in that it
can be added to and removed from a particular
protein multiple times during its lifespan, makes this
modification similar in some regard to protein
phosphorylation [21]. However, whereas the role of
phosphorylation on the aggregation of tau has been
studied in detail [22–25], that of O-GlcNAc is poorly
defined.
Various studies have suggested that O-GlcNAc
present on tau plays a role in AD. First, Lefebvre et al.
and Liu et al. have demonstrated that human tau is
indeed O-GlcNAc modified and that O-GlcNAcylation
can be reciprocal to tau phosphorylation [26,27].
Increased O-GlcNAc on tau is correlated with de-
creased phosphorylation and vice versa, at least in cell
culture and ex vivo in tissue slices [26,27]. Second,
Robertson et al. have shown that the O-GlcNAc
levels of a tau-enriched fraction from the AD brain are
significantly reduced as compared to age-matched
healthy controls [28] and NFTs appear to completely
lack O-GlcNAc [27]. This is notable because UDP-
GlcNAc, the sugar donor substrate used by OGT, is
derived from cellular glucose [29], which makes
O-GlcNAc levels sensitive to changes in metabolism
[30]. Given that impairment of glucose utilization in the
AD brain is well described [31], it has been proposed
[27] that decreased glucose utilization in the AD brain
gives rise to lower UDP-GlcNAc levels, which in turn
result in lower levels of tau O-GlcNAcylation and
consequently higher levels of tau phosphorylation
[27]. We initially speculated that, if one could increase
levels of O-GlcNAc in vivo, tau phosphorylation
might be reduced, which in turn could slow tau-driven
neurodegeneration.
To test this hypothesis in vivo, we used Thiamet-G,
a potent and selective OGA inhibitor, to increase
O-GlcNAc levels on tau in the brains of JNPL3
transgenic mice [32]. This mouse model expresses
a mutant form of human tau that becomes hyperpho-
sphorylated and aggregates within the brain and
spinal cord to formNFTs [33].We found that treatment
of these transgenic mice with Thiamet-G led to a
decrease in the number of NFTs in their brains and
spinal cords but did not prevent tau hyperphosphor-ylation [32]. We cannot, however, rule out changes in
tau phosphorylation at specific sites not studied in that
work. We further showed that O-GlcNAc modification
of a truncated form of recombinant tau, devoid of
phosphorylation, inhibited its aggregation in vitro [32].
Collectively, these data suggest thatO-GlcNAc on tau
may act to directly inhibit its aggregation. However,
more detailed studies on the role of O-GlcNAc on
aggregation of different human tau constructs, includ-
ing the full-length protein, have not been performed.
To address whether O-GlcNAc modification of tau
can influence its aggregation, we have recombinantly
produced the longest human isoform of tau (Tau441)
in both its unmodified and its O-GlcNAc-modified
states. Using this material, we show that O-GlcNAc
modification inhibits tau aggregation in vitro. Further,
we find that this decreased rate of tau aggregation
does not appear to be due to global structural changes
in monomeric tau prior to its aggregation. In support
of this conclusion, nuclear magnetic resonance
(NMR) spectroscopic studies using a fragment of tau
(residues 353–408) confirm minimal local structural
and dynamic changes in the disordered polypeptide
upon O-GlcNAc modification. Collectively, these data
suggest that the effects ofO-GlcNAc on tau aggrega-
tion result from enhanced monomer solubility or the
destabilization of fibrils or soluble aggregates, rather
than by altering the conformational properties of the
monomeric protein.
Results and Discussion
Sample preparation
As shown previously, we have demonstrated that
O-GlcNAc-modified Tau441 can be made recombi-
nantly by co-expression of OGT and Tau441 in
Escherichia coli [34]. However, while useful for
mapping O-GlcNAc modification sites, this material
was insufficiently pure to allow informative biochem-
ical studies. To obtain higher purity O-GlcNAc-
modified tau, we have now used high-performance
liquid chromatography (HPLC) to produce both
control Tau441 (cTau441wt, expressed with the
catalytically inactive H558A OGT mutant, mutOGT)
and O-GlcNAc-modified Tau441 (ogTau441wt,
expressed with wild-type OGT, wtOGT) having a
high level of purity and an absence of degradation
products (Fig. 1a). We have also investigated a
mutant form of Tau441 that has the major site of
O-GlcNAcylation (Ser400) [34–36] mutated to ala-
nine. This mutant tau was expressed recombinantly
with mutOGT and wtOGT to produce control S400A
Tau441 (cTau441S400A) and O-GlcNAc-modified
S400A Tau441 (ogTau441S400A), respectively
(Fig. 1a). Immunoblotting with a pan-specific
O-GlcNAc antibody (CTD110.6) indicated that the
S400A mutation resulted in approximately 2-fold less
Fig. 1. Production of O-GlcNAc Tau441 and catalysis of microtubule polymerization. (a) Coomassie blue
(CB)-stained SDS-PAGE gel (upper panel): Lane 1, cTau441wt; Lane 2, ogTau441wt; Lane 3, cTau441S400A; and Lane 4,
ogTau441S400A. Total tau (Tau-46) immunoblot also indicates equal tau loading in all lanes.O-GlcNAc immunoblot with the
pan-specific O-GlcNAc antibody, CTD110.6, indicates that only ogTau441wt and ogTau441S400A bear O-GlcNAc and that
O-GlcNAc levels are ~50% lower in the ogTau441S400A sample. Finally, the Ser400 O-GlcNAc tau antibody, 3925, only
detects O-GlcNAc at Ser400 on the ogTau441wt sample. ESI-MS reconstructed mass spectra of (b) cTau441wt and
(c) ogTau441wt indicate that the ogTau441wt contains ~60% O-GlcNAc. The (*) symbol identifies the α-N-gluconoylated
peaks. (d) Tubulin polymerization assays of cTau441wt and ogTau441wt indicate that O-GlcNAc does not impair or
enhance microtubule polymerization. (e) Tubulin polymerization assays of cTau441S400A and ogTau441S400A also show
that reduced O-GlcNAc levels do not affect microtubule polymerization.O-GlcNAc on ogTau441S400A versus ogTau441wt.
This is consistent with Ser400 being a major site of
modification by OGT. Electrospray ionization mass
spectrometry (ESI-MS) of cTau441wt (Fig. 1b) and
ogTau441wt (Fig. 1c) showed that the latter contains
~60% O-GlcNAc and ~40% unmodified Tau441wt.
On average, the population of O-GlcNAc-modified
Tau441 had ~1.5 O-GlcNAc residues per protein
molecule. We also detected a signal of 178 Da
increased mass that is consistent with some (b20%)
α-N-gluconoylation of the His6-tag [37] of both the
cTau441wt and the ogTau441wt. The extent of this
modification, which is known to occur on proteins
recombinantly produced in E. coli [37–40], did not
differ between the cTau441wt and the ogTau441wt
(Fig. 1b and c).Tubulin polymerization is independent of tau
O-GlcNAcylation
To date, the only clearly assigned functions of tau
are to bind to and stabilize microtubules [41]. For this
reason, we were interested in whether O-GlcNAc
modification of tau might alter its ability to affect
microtubule polymerization. We therefore assayed
the capacity of cTau441wt and ogTau441wt to promote
tubulin polymerization and observed that both en-
hanced tubulin polymerization to similar extents
(Fig. 1d). cTau441S400A and ogTau441S400A also
showed no significant difference in their ability to
enhance the rate of, or extent of, tubulin polymeriza-
tion (Fig. 1e). However, the S400A mutation resulted
in an approximately 3-fold decrease in the growth rate
of the tubulin polymer, as compared to wild-type
Tau441, even though both Tau441S400A and
Tau441wt were used at equivalent concentrations.
These values were obtained by fitting the tubulin
polymerization curves to a Gompertz model of growth
[42].
O-GlcNAcylation inhibits Tau441 aggregation
We previously showed that O-GlcNAc on a
truncated form of tau inhibits its aggregation in vitro
[32]. To test whether O-GlcNAc acts to inhibit
aggregation of full-length Tau441, we conducted
in vitro aggregation assays using solutions contain-
ing both 10 μM tau and 10 μM heparin. Because of
the unusually highly charged nature of tau and its
paucity of aromatic amino acid residues, which
makes tau behave differently from other proteins in
many assays, careful measurement of its concen-
tration prior to conducting the aggregation assays is
important. As described below in Materials and
Methods, this was achieved using three different
approaches. Aggregation of these carefully stan-
dardized samples was then monitored by fluores-
cence spectroscopy using Thioflavin-S (ThS), which
is known to bind preferentially to tau aggregates
over tau free in solution [43]. Both cTau441wt and
ogTau441wt aggregated over a period of 3 days with
no readily apparent lag phase, and the resulting data
were well fit to a single exponential growth curve.
However, ogTau441wt aggregated more slowly and
reached an equilibrium (plateau) value ~1.3-fold
lower than that of cTau441wt (Fig. 2a). To probe this
result via an independent method, we used an
established filter-trap assay [44]. We found that this
assay also detected a similar ~1.3-fold lower
equilibrium position for ogTau441wt as compared to
cTau441wt (Fig. 2b). Given that tau aggregates via aFig. 2. O-GlcNAc modification causes slower aggregat
ogTau441wt aggregation over a period of 3 days using 10 μM
more slowly than cTau441wt and reaches a lower equilibriu
ogTau441wt aggregation also demonstrates that ogTau441wt r
cTau441wt. *P b 0.05 (two-tailed unpaired t-test), whereas n.s i
of the mean and lines represent exponential fits.nucleation-dependent mechanism, the equilibrium
position in such a model is controlled by the
post-nuclear extension and contraction of tau fibrils.
These data thus suggest that O-GlcNAc reduces the
extension rate or increases the contraction rate of
tau fibrils.
The observation that there is only ~60%O-GlcNAc-
modified Tau441 in the ogTau441wt samples may
obscure aspects of the observed aggregation. To
acquire more detailed information, we set out to
enrich further the quantity of O-GlcNAc-modified
Tau441 in the ogTau441wt sample. Prior to enrich-
ment, we also cleaved the His6-tag from tau using
thrombin to eliminate any potential impact of the tag
and the small quantity of α-N-gluconoylated product
mentioned above. To remove unmodified tau from
this ogTau441wt sample, we conducted another
round of HPLC purification using a very shallow
gradient of 30–35% acetonitrile:water. These chro-
matography conditions resulted in two distinct peaks
(Fig. 3a) that we speculated arose from O-GlcNAc-
modified and unmodified Tau441 within the
ogTau441wt preparations. Analysis of these fractions
by immunoblotting using the Tau-46 antibody, which
recognizes the C-terminus of tau, and the tau
O-GlcNAc-Ser400 antibody 3925 [34] revealed that
the earlier eluting peak was indeed due toO-GlcNAc-
modified Tau441, whereas the later eluting peak
stemmed from unmodified Tau441 present within the
sample (Fig. 3a). The ability of such a small number of
monosaccharides to influence the hydrophobicity of
full-length tau, as reflected in these differences in
chromatographic mobility, is striking. When the
fractions corresponding to the earlier eluting peak
were combined and compared to the ogTau441wt
samples used in studies shown in Fig. 1, we found an
approximately 2-fold enrichment in O-GlcNAc as
estimated by immunoblotting (Fig. 3a and b). Weion of Tau441. (a) ThS binding assay of cTau441wt and
protein and 10 μM heparin. The ogTau441wt aggregates
m plateau value. (b) Filter-trap assay of cTau441wt and
eaches an equilibrium position that is ~1.3-fold lower than
ndicates not significant. Error bars represent standard error
Fig. 3. O-GlcNAc-modified Tau441 can be enriched to near stoichiometric quantities. (a) ogTau441wt can be
separated from unmodified Tau441 by reversed phase HPLC. The black HPLC trace indicates that there are two peaks
that elute between 28 and 40 min. Using immunoblot analyses of fractions from this region for total tau and for O-GlcNAc
[shown in the lower panel and with densitometry plotted in red squares (O-GlcNAc) and gray triangles (total tau)], it can be
seen that the earlier eluting peak stems from the O-GlcNAc-modified Tau441. (b and c) Characterization of the enriched
material compared to ogTau441wt and cTau441wt shows an approximately 2-fold enrichment of O-GlcNAc-modified tau
(referred to as enriched O-GlcNAc Tau441, EogTau441wt: Lane 1, cTau441wt; Lane 2, ogTau441wt; Lane 3, cTau441wt;
Lane 4, EogTau441wt). (d) ESI-MS analysis shows that the EogTau441wt material is ~98% O-GlcNAc-modified tau and
contains almost no unmodified Tau441wt.refer to this sample as enriched ogTau441wt
(EogTau441wt). Analysis of EogTau441wt by ESI-MS
reveals that tau is ~98%O-GlcNAc modified (Fig. 3d).
Technical challenges associated with this
HPLC enrichment strategy limited the amount of
EogTau441wt that could be obtained in high purity.
Nevertheless, we were able to produce enough
material to compare the aggregation propensities of
the EogTau441wt (no His6-tag) and cTau441wt
(no His6-tag).We first sought tomeasure the progress
of tau aggregation over a period of 8 days using ThS
fluorescence (Fig. 4). Aggregation was monitored
over a longer period of time because the limitedamount of EogTau441wt necessitated using this
material at a concentration of 5 μM with 10 μM
heparin. As can be seen in Fig. 5, both EogTau441wt
and cTau441wt aggregated with a noticeable lag
phase. The appearance of a lag phase compared to
ogTau441wt (Fig. 2) likely results from the lower
EogTau441wt concentration (5 μM), which is close to
the critical concentration for tau aggregation (~2 μM).
This behavior has been described previously for other
tau constructs, where tau concentrations close to the
critical concentration leads to greatly decreased
aggregation rates and the emergence of a lag phase
[43,45]. When fit to a Gompertz model of growth, the
Fig. 4. O-GlcNAc modification of Tau441wt slows
both nucleation and extension steps of tau aggregation
in vitro. Aggregation of 5 μM cTau441wt and EogTau441wt
(both without His6-tags) in the presence of 10 μM heparin
was followed for 8 days using ThS fluorescence.
EogTau441wt displays a pronounced lag phase, as well as
a significantly lower equilibriumplateau. Error bars represent
standard error of the mean and lines represent fits to the
Gompertz model. Using a two-tailed student's unpaired
t-test, (*) indicates P b 0.005 and (#) indicates P b 0.05.EogTau441wt exhibited a significantly longer lag time
of 1.64 ± 0.64 days compared to 0.47 ± 0.16 days
for cTau441wt (Fig. 5). We also noted a 3-fold lower
equilibriumposition for theEogTau441wt as compared
to the cTau441wt sample. Based on the ESI-MS data
for EogTau441wt (Fig. 3d), it is evident that this HPLC
purification method enriches the doubly and triply
O-GlcNAc-modified tau species. However, because
these aggregation studies are population-based
averages, we cannot distinguish the effects of single,
double, or triple O-GlcNAc modifications of
EogTau441wt. Indeed, it is possible that sites other
than Ser400 may contribute to a greater extent to
slowing tau aggregation. Nevertheless, these data
indicate that the O-GlcNAc on Tau441 slows the
nucleation phase of aggregation in vitro, as well as
impacting the extension or contraction rates of the
resulting Tau441 aggregates.
O-GlcNAcylationdoesnot perturb the “global-fold”
of Tau441
One possible way in which O-GlcNAc on Tau441
might inhibit the nucleation or extension of filaments
in vitro is by altering its conformation. Such a
conformational change could impair formation of
fully aggregation competent nuclei. Using Förster
resonance energy transfer (FRET) to measure aver-
age intermolecular distances between features in the
primary structure of tau, Jeganathan et al. have shown
that tau can adopt a global-fold [46]. In this fold, the
C-terminal domain of tau packs close to the microtu-
bule binding repeats and the N-terminal domainpacks near the C-terminal domain, thereby creating
a “paper-clip” structure [46]. “Pseudophosphorylation”
(serine-to-glutamate mutations) mutations of tau at
the paired helical filament-1 antibody epitope
(pSer396/404) can drive compaction of the paper-clip
structure and facilitate tau aggregation in vitro [23,46].
Due to the apparent reciprocal relationship between
phosphorylation andO-GlcNAc on tau observed in the
short term upon treatment with inhibitors [27,47],
coupled with the effects of Ser396/404 pseudopho-
sphorylation on the global-fold [23], we envisioned a
scenario whereinO-GlcNAc could hinder compaction
of the paper-clip structure and thereby diminish the
aggregation propensity of tau.O-GlcNAc on tau could,
for example, disfavor approach of the C-terminal
region of tau toward the microtubule binding repeats
and thus inhibit its aggregation. To test this possibility,
we generated the Tau441 (C291S/V432W) double
mutant, which was previously described by Jega-
nathan et al. [23,46], and then co-expressed this
protein in the presence of mutOGT or wtOGT. The
control (cTau441C291S/V432W) and the O-GlcNAc-
modified (ogTau441C291S/V432W) forms were labeled
at the remaining sole cysteine residue (Cys322) with
the 1,5-IAEDANS fluorescent probe and then purified
by HPLC. The ogTau441*C291S/V432W (* indicating that
the protein is labeled with IAEDANS) produced in this
manner is both of high purity (Fig. 5a) and O-GlcNAc
modified (Fig. 5b). During SDS-PAGE analysis, only
the samples labeled with IAEDANS showed a fluores-
cence signal at 336 nm (Fig. 5b, lower panel).
Using these samples, we measured the FRET
efficiency between the donor Trp432 and the acceptor
IAEDANS-labeled Cys322. A reduction in tryptophan
fluorescence at approximately 350 nm and the
appearance of an IAEDANS emission band at
490 nm indicated that energy transfer occurred
between these two positions as previously reported
[46]. We observed similar low FRET efficiencies for
both cTau441*C291S/V432W and ogTau441*C291S/V432W
from which ensemble-averaged distances of ~36 Å
(±17 Å) between the IAEDANS and W432 were
calculated (Fig. 5c and d). These distances,
determined by assuming the published relationship
between FRET efficiency and donor–acceptor sep-
aration [46], differ somewhat from the previously
reported value of 22.5 Å [46]. The reasons for this
difference remain unclear, though they may reflect
variations in the sample buffers, concentrations
of the analytes, or cuvette path length. Additionally,
we cannot eliminate that our purification protocol,
which includes HPLC separation, might eliminate
the paper-clip structure. We note, however, that
formation and stability of the paper-clip structure
should be thermodynamically controlled and thus
not impacted by the purification protocol. Regard-
less, when analyzing these data, we observed
that O-GlcNAc had no effect on the global-fold
of tau in solution as measured using these FRET
Fig. 5. O-GlcNAc modification of Tau441 does not alter the global-fold in solution. (a) Coomassie blue-stained
SDS-PAGE gel of Lane 1 cTau441C291S/V432W (no IAEDANS), Lane 2 cTau441*C291S/V432W (IAEDANS-modified), Lane 3
ogTau441C291S/V432W (no IAEDANS), Lane 4 ogTau441*C291S/V432W (IAEDANS-modified). (b) (top) Total tau immunoblot
(Tau-46) indicates equal tau loading in all lanes. (middle)O-GlcNAcWestern blot with the pan-specificO-GlcNAc antibody,
CTD110.6, indicates that only ogTau441C291S/V432W and ogTau441*C291S/V432W bear O-GlcNAc. The Ser400 O-GlcNAc
tau antibody, 3925, only detects O-GlcNAc on Ser400 on the ogTau441C291S/V432W and ogTau441*C291S/V432W samples.
(bottom) Image captured using 336 nm light box indicates that only the IAEDANS-modified samples show fluorescence in
an SDS-PAGE gel. (c and d) Both cTau441*C291S/V432W and ogTau441*C291S/V432W show limited FRET between Trp432
and IAEDANS-labeled Cys322 as evidenced by the minor decrease in tryptophan fluorescence in the presence of the
IAEDANS label. (e and f) The addition of 8 μM heparin to the cTau441*C291S/V432W and ogTau441*C291S/V432W does not
result in any increase in FRET between Trp432 and the IAEDANS label at Cys322.assays. We also added heparin to the FRET samples
to assess whether the presence of an inducer of
aggregation results in a change in the global-fold.
Over the course of 5 min after the addition of heparin,
we observed no significant difference between theFRET efficiencies of ogTau441*C291S/V432W and
cTau441*C291S/V432W (Fig. 5e and f), indicating that
heparin has no measurable effect on the global
conformation of tau regardless of its O-GlcNAc
modification state.
O-GlcNAcylation of Ser400 does not perturb the
local conformation or dynamics of Tau353-408
Since we observed no changes in the global-fold
of Tau441 due to GlcNAc modification, we used
NMR spectroscopy to test the possibility that
structural or dynamic perturbations may occur in a
more localized manner around the site of modifica-
tion. However, full-length Tau441 is challenging to
study due to its large size and intrinsic disorder,
which leads to extensive spectral overlap [48,49].
Accordingly, we turned to a fragment Tau353-408
(residues 353–408) spanning the region from the last
microtubule binding repeat to the major GlcNAc-G366 
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vation, in effect, provided uswith an internal control for
studying the modified and unmodified peptides under
identical experimental conditions. A comparison of the
two spectra showed that only a limited number of
amides near Ser400 had perturbed amide 1HN and
15N chemical shifts (Fig. 7a). This result both
confirmed that Ser400 is the sole site of modification
and again indicated that there were no “global”
structural changes within this peptide arising from0 
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Fig. 7. O-GlcNAcylation of Ser400 does not perturb the lo
chemical shift differences {Δδ = [(Δδ1H)
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cTau353-408. Modest perturbations occurred only near th
perturbations clustered around histidine residues. This most l
close to the pKa ~ 6 for a histidine side chain. (b) Both ogT
random-coil propensities based on an analysis of their main
small apparent increase in random-coil propensities for the C
is accompanied by a corresponding decrease in β-strand
(c) Heteronuclear 15N-NOE values of ogTau353-408 (includ
Errors are approximately ±0.05. NOE values decreasing from a
the amide 1HN–15N bond on the sub-nanosecond timesca
random-coil peptides when recorded with an 850 MHz NMR sp
both peptides, as well as the GlcNAc, are conformationally d
ogTau353-408 have marginally increased NOE values com
results slightly in locally increased conformational rigidity on ththe presence of O-GlcNAc. A similar conclusion was
reported based on NMR spectroscopic studies of the
effects of Ser400O-GlcNAc modification on a smaller
tau fragment (residues 392–411) [35].
We calculated the secondary structure propensities
of cTau353-408 and ogTau353-408 from main-chain
chemical shifts (1HN, 1Hα, 13Cα, 13Cβ, 13CO, and
15N), using the algorithm δ2D, which is specifically
calibrated for intrinsically disordered proteins [50]. As
summarized in Fig. 7b and Fig. S1, both cTau353-408
and ogTau353-408 are intrinsically disordered with
very high overall random coil and some localized
polyproline type II helical propensities. Importantly,
the presence of O-GlcNAc did not change these
patterns, except for a very slight increase in predicted
β-sheet propensity for residues immediately adjacentE
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Fig. 8. O-GlcNAc modification also inhibits the
aggregation of Tau353-408. The aggregation of 50 μM
cTau353-408 (black circles) and EogTau353-408 (red
triangles) in the presence of 12.5 μMheparin wasmonitored
at 37 °C using ThS fluorescence. The O-GlcNAc-modified
EogTau353-408 aggregated slower and reached a lower
plateau fluorescence value relative than did the unmodified
cTau353-408. Also presented is a no protein control (gray
diamonds). Average data for triplicates are shown alongwith
error bars representing standard deviations (someerror bars
are smaller than the symbols). Lines are the bests fit to an
exponential growth curve.to Ser400 and a decrease for residues toward the
C-terminus of the polypeptide (Fig. S1). We believe
that this is of questionable significance, given that the
algorithm was not calibrated with glycopeptide refer-
ence chemical shifts. Also, the backbone ϕ dihedral
angle-dependent 3JHN-Hα couplings measured for
both cTau353-408 and ogTau353-408 are indicative
of random-coil conformations (Fig. S2). In parallel, we
also compared the fast sub-nanosecond timescale
amide motions of ogTau353-408 and cTau353-408
using heteronuclear 15N-nuclear Overhauser effect
(NOE) experiments (Fig. 7c). These measurements
supported the conclusion that both peptides are
conformationally dynamic. However, residues near
theO-GlcNAc-modified Ser400 of ogTau353-408 had
increased NOE values compared to those in
cTau353-408, suggestive of reduced conformational
flexibility on the nanosecond-to-picosecond time-
scale. Collectively, these NMR measurements re-
vealed that Tau353-408 is intrinsically disordered
and that the O-GlcNAc modification only dampened
fast backbone motions in the region immediately
surrounding residue 400.
O-GlcNAcylation of Ser400 does not perturb the
X-Pro cis/trans conformational equilibria of Tau
We noted that the 15N-HSQC spectra of
cTau353-408 and ogTau353-408 also contained a
weak subset of peaks for amides flanking the three
proline residues within these fragments (Fig. 6).
Based on diagnostic proline 13Cβ versus 13Cγ
chemical shift differences [53], we unambiguously
assigned these to a population of conformers with
Val363-Pro364, Ser396-Pro397, or Ser404-Pro405
having a cis peptide bond (Fig. S3). Notably, Pro397
and Pro405 are proximal to the site of O-GlcNAc
modification and adjacent to Ser396 and Ser404,
both of which are often phosphorylated during tau
pathogenesis. Accordingly, we investigated whether
the O-GlcNAc modification perturbed the cis/trans
ratios for Tau353-408. As summarized in Table S1,
the relative populations of the cis conformers did
not differ significantly between cTau353-408 and
ogTau353-408. This observation provided further
evidence that the O-GlcNAc modification of Ser400
did not measurably alter the conformation of tau.
2.7. Tau-linked O-GlcNAc is conformationally
dynamic
The 15N-HSQC (Fig. 6) and 13C-HSQC spectra
(Fig. S4) of ogTau353-408 also contain well-resolved
signals from theO-GlcNAcmoiety. These signals also
allowed us to use NMR methods to investigate
mobility of the O-GlcNAc residue itself. The hetero-
nuclear 15N-NOE value of the GlcNAc amide is −0.1,
demonstrating that this residue is very mobile on the
sub-nanosecond timescale (Fig. 7c). Supporting thisconclusion, 1H–1H NOEs observed for the GlcNAc
acetamido group were only from adjacent protons
on the monosaccharide ring and not the protein
component of ogTau353-408 (Fig. S4). Therefore, the
Ser400-linked O-GlcNAc is not conformationally
restrained by any non-covalent interactions with the
polypeptide.
O-GlcNAcylation also decreases Tau353-408
aggregation propensity
Given that no effects of O-GlcNAc on peptide
conformation were observed for the Tau353-408
samples beyond the site of modification, we asked
whether these truncated proteins showed decreased
aggregation propensity as seen for ogTau441. To
test this idea, we carried out in vitro ThS-monitored
aggregation assays using 50 μM cTau353-408
or EogTau353-408 with 12.5 μM heparin. Eog-
Tau353-408 was obtained by using a second
HPLC purification step and has a higher level
(~88%) of O-GlcNAc modification. We determined
the concentration of the cTau353-408 and Eog-
Tau353-408 samples using two different ap-
proaches, as outlined in Materials and Methods.
With these standardized solutions of the tau frag-
ments, we found that EogTau353-408 both showed
a significantly diminished rate of aggregation and
reached an ~2.5-fold lower equilibrium value as
compared to cTau353-408 when fit to a single
exponential growth model (Fig. 8). This result
is strikingly similar to that of the corresponding
EogTau441wt versus cTau441wt. It is important to
note that these measurements were carried out by
different personnel in different laboratories, yet both
showed that the O-GlcNAc modification perturbs
the aggregation of full-length tau and a tau fragment
containing Ser400.
Conclusions
The O-GlcNAc modification has gained increasing
attention as its cellular roles are gradually being
uncovered. However, the biochemical effects of
O-GlcNAc modification on most proteins remain
unclear. Interest in the function of O-GlcNAc on
tau has been fueled by recent observations that
(i) it occurs within humans with the primary modifi-
cation site being Ser400 [34–36], (ii) O-GlcNAc
modification of tau is not found within NFTs [27],
(iii) increased O-GlcNAc modification in the brain
protects against tau-induced neurodegeneration
[32], and (iv) O-GlcNAc decreases the aggregation
propensity of a truncated tau construct [32]. Here
we analyzed the biochemical effects of O-GlcNAc
modification on full-length tau, as well as on a
truncated tau construct incorporating Ser400. We
find that O-GlcNAc on the full-length human isoform
of tau does not impact its ability to bind to and
stabilize microtubules. However, the modification
does inhibit aggregation of full-length Tau441wt
in vitro. Based on these results, O-GlcNAc at Ser400
appears to play a role in hindering tau aggregation.
Although not tested in this study, the effect of
O-GlcNAc at other sites may have similar or even
greater effects on aggregation. This inhibition of
tau aggregation appeared to be driven principally by
slowing the extension phase of aggregation and
perturbing the equilibrium position between oligomers
and free tau. To evaluate the basis for these effects,
we performed biophysical studies on various tau
constructs.
Analysesof Tau441byFRET indicated that there are
no gross structural differences between cTau441wt and
ogTau441wt. Thus, the effect of O-GlcNAc does not
appear to arise from any ensemble-averaged chang-
es in its global-fold within solution. Analysis of more
localized effects of O-GlcNAcylation, performed using
a fragment of tau that is readily amenable to NMR
spectroscopic analysis, showed that O-GlcNAc had
no effect on the extent of intrinsic disorder. This
conclusion follows from the lack of any substantial
changes in the main-chain chemical shifts, 3JHN-Hα
couplings, and heteronuclear 15N-NOE values of the
Tau353-408 fragments, all of which are diagnostic of
dynamically averaged random-coil conformations.
O-GlcNAcylation of Ser400 also had no obvious
effect on the extent of cis/trans isomerization equilibria
of prolines within this tau fragment. We did observe
chemical shift perturbations and slightly increased
heteronuclear 15N-NOE values for amides adjacent toSer400, suggesting subtle conformational changes
and a dampening of their fast timescalemotionswithin
the regions immediately surrounding the site of
O-GlcNAc modification. However, no interproton
NOEs between the O-GlcNAc and the polypeptide
chain were observed, and 15N-NOE measurements
revealed that its amidemoiety is also conformationally
mobile. Collectively, these experiments demonstrated
that O-GlcNAcylation of Ser400 at best only causes
small, localized changes to the structure and dynam-
ics cTau353-408. Despite the lack of major effects on
tau conformation or dynamics, O-GlcNAcylation of
Ser400 dramatically retards the aggregation of both
Tau353-408 and full-length tau in vitro.
These collective observations are worth considering
in light of several existing studies of tau and various
glycopeptides.A limited number ofNMR-basedstudies
of glycopeptides have indicated that O-glycosylation
favors turn conformations in residues flanking the site
of modification, possibly through water-mediated
hydrogen bonds between the sugar and polypeptide
backbone [54–59]. Also, O-GalNAc modification of
serine and threonine residues of the hinge peptide of
serum immunoglobulin A1 reduces the cis/trans ratio
of immediately adjacent proline residues [60]. These
effects, however, are likely context dependent and in
all cases were localized to the region of modification.
The ability of O-GlcNAcylation of Ser400 to influence
the aggregation propensity of both Tau441wt and
Tau353-408 is therefore remarkable, given that this
site is relatively distant from and has no effect on the
conformation of the microtubule binding repeats,
which are required for tau aggregation.
In the absence of any detectable effects on tau
conformation, O-GlcNAc modification of tau may
decrease its aggregation propensity by enhancing its
solubility as seen for keratin [61] or it may also impair
its ability to be efficiently incorporated within ordered
tau oligomers or otherwise destabilize fibrils into
which it is incorporated. The results described here
are in clear contrastwith the effects of phosphorylation
on aggregation of Tau441. For Tau441, pseudopho-
sphorylation increases both the rate of nucleation and
the amount of tau fibrils at equilibrium by stabilizing
tau fibrils against disassembly [24,25,62]. This
work on O-GlcNAc therefore highlights the fact that
different post-translational modifications of tau can
have dramatically different effects on its aggregation
in vitro. It is also consistent with the observation that
these modifications play substantially different roles
in the pathogenesis of AD. Modifications such as
tau phosphorylation and proteolysis likely provide
a driving force for tau-linked neurodegeneration in
AD. TheO-GlcNAcmodification, however, may play a
protective role in tau biology, and the aggregation
of tau in the AD brain might result in part from a failure
in such a protective function. Indeed, the results
described here, alongside the established protective
effects of increased O-GlcNAc in transgenic tau
models [32] and the absence of O-GlcNAc-modified
tau within NFTs [27], support a role for O-GlcNAc
modification of tau in limiting its aggregation in vivo.
Collectively, these observations suggest that in-
creased O-GlcNAc in the brain may diminish tau
toxicity by hindering its ability to form oligomers. This
further underscores the potential of this pathway for
potential AD therapeutics.Materials and Methods
O-GlcNAc-modified Tau441 production and purification
pET28a vectors containing the coding sequence of
either Tau441wt or Tau441S400A were co-transformed with
pMal-c2X vectors encoding wild-type OGT (wtOGT) or
H558A OGT (mutOGT) into E. coli Tuner cells (Strata-
gene). To induce expression of Tau441wt or Tau441S400A,
we added IPTG (0.5 mM) to the co-transformants, and
they were cultured overnight at 22 °C for ~20 h. The
bacterial cells were harvested by centrifugation at
5000 rpm for 10 min in a Sorvall RC-6 Plus centrifuge in
a FIBERLite F9S-4x1000y rotor. The bacterial pellets were
then resuspended in 30 mL of Ni-NTA column binding
buffer (20 mM sodium phosphate, 500 mM NaCl, 5 mM
imidazole, pH 7.4). Pellets containing wtOGT/Tau441wt,
mutOGT/Tau441wt, wtOGT/Tau441S400A, and mutOGT/
Tau441S400A were lysed by the addition of 2 mg/mL
lysozyme (Bioshop) in the presence of one Roche
protease Complete tablet per 30 mL of resuspended
bacterial pellet. Disruption of the samples, maintained on
ice, was carried out with a Fischer Scientific sonic
dismembrator (model 500) using six cycles of 20 s of
sonication at 30% power, followed by a 40-s cooling
period. Cellular debris were removed by centrifugation at
13,000 rpm in an SS-34 rotor in a Sorvall RC-6 Plus
centrifuge. The clarified supernatant from each sample
was then loaded onto HisTrap FF Ni-NTA columns (GE
Healthcare), which was washed with 90 mL of Ni-NTA
column wash buffer (20 mM sodium phosphate, 500 mM
NaCl, 60 mM imidazole, pH 7.4) and eluted with 25 mL of
Ni-NTA column elution buffer (20 mM sodium phosphate,
500 mM NaCl, 250 mM imidazole, pH 7.4). The eluates
were then dialyzed three times against 20 mM sodium
phosphate buffer, pH 6.7, and concentrated to 2 mL using
an Amicon centrifugal filter.
The Tau441 protein samples (0.25 mg per HPLC run)
were acidified using 10% trifluoroacetic acid (TFA) to
generate a final TFA concentration of 0.1% (v/v) and loaded
onto an Agilent Zorbax 300SB-C8 (9.4 mm × 250 mm)
semi-preparative HPLC column housed in an 1100 series
Agilent HPLC. The column was held at 30% buffer B
[acetonitrile (CH3CN):water, 0.1% TFA] for the first 5 min,
after which the proteinswere eluted using a linear gradient of
30–75% CH3CN over 45 min using a flow rate of 1 mL/min.
Fractions (1 mL) were collected using a Foxy Jr. fraction
collector over the entirety of the HPLC run, and those
containing ogTau441 were pooled and lyophilized to
dryness. The cTau441wt and ogTau441wt or cTau441S400A
and ogTau441S400A samples were taken up in 1 mL of
20 mM sodium phosphate buffer, pH 7. Samples were
assessed for purity by analysis using 12%SDS-PAGE gels,and the concentration of protein in the sample was
measured as described below.
Due to some of the unusual physical properties of tau
protein, such as its high isoelectric point and the paucity of
aromatic amino acids, careful concentration measurements
were necessary to avoid systematic errors within these
studies. Three different approaches were used to establish
equivalent concentrations of the cTau441wt, ogTau441wt,
cTau441S400A, and ogTauS400A samples used in the assays.
First, the concentration of each of these samples was
determined using the Bio-Rad DC assay using BSA (bovine
serum albumin) as a standard, according to the manufac-
turer's protocol. Based on the results of the DC assay
(a detergent-compatible proprietary modification of the
Lowry method), an SDS-PAGE gel was loaded to include
equivalent quantitiesof each of these samples.After staining
with Coomassie brilliant blue dye, densitometry of the
SDS-PAGE gel confirmed that equivalent quantities of
each of these species had indeed been loaded (Fig. 1a).
This analysis provided confidence that the concentrations of
each of these samples can be measured accurately using
the Bio-Rad DC assay. Third, a total tau enzyme-linked
immunosorbent assay (ELISA) was developed and used to
assay both the cTau441wt and the ogTau441wt samples.
The sandwich ELISA involved the use of BT-2 as the tau
capture antibody, immobilized on Maxisorp 96-well ELISA
plates, followed by use of the Tau-5 tau antibody for
detection. Each of these samples was serially diluted from
10,000 pg/mL (based on the DC assay result) down to a
concentration of 10 pg/mL, and the signal from the total tau
ELISA was determined. This analysis showed that indeed
the concentrations of the cTau441wt and the ogTau441wt
established using the Bio-Rad DC assay are equivalent
within the error of the assays, again giving high confidence
that the DC assay provides accurate determinations of the
total tau concentration (Fig. S5).
HPLC enrichment of O-GlcNAc-modified Tau441
Prior to HPLC enrichment, the cTau441wt and ogTau441wt
samples were treated with thrombin (Roche) in a 1:8 (w/w)
tau-to-thrombin mass ratio for 20 min at RT (room tempera-
ture). Following cleavage, 1 mM phenylmethylsulfonyl fluo-
ride (PMSF) was added to stop the protease digestions. The
ogTau441wt protein (0.25 mg per HPLC run) was acidified
using10%TFAand loadedonto anAgilent Zorbax300SB-C8
(9.4 mm × 250 mm) semi-preparative HPLC column housed
in an 1100 series Agilent HPLC. The proteins were eluted
using a linear gradient of 30–35%CH3CN over 95 min with a
flow rate of 1 mL/min. The fractions containing cTau441wt and
ogTau441wt were pooled and lyophilized to dryness. The
enriched ogTau441wt sample (referred to as EogTau441wt)
was dissolved in 1 mL of 20 mM sodium phosphate buffer,
pH 7, and underwent a second round of HPLC purification.
Samples were assessed for their level of purity using 12%
SDS-PAGE analysis in conjunction with Coomassie blue
staining. The concentration of tau was determined as
described above.
Tau353-408 expression and purification
A gene encoding residues 353–408 of tau preceded by
His6-SUMO was cloned into the pET28a plasmid and
co-transformed into E. coli BL21(λDE3) cells along with
vectors encoding wtOGT and mutOGT, as described
above. Unlabeled protein was produced in LB media,
whereas M9 minimal media supplemented with 1 g/L
15NH4Cl and/or 3 g/L
13C6-glucose was used to produce
labeled protein. When the OD600 reached 0.6, protein
expression was induced with 0.5 mM IPTG, followed by
culture growth overnight at 16 ºC. Cells were harvested by
centrifugation at 4000g in a GSA rotor (Sorvall) for 15 min.
After one freeze–thaw cycle, the cell pellet was resus-
pended in column binding buffer with ~2 mg/mL lysozyme.
Cells were then disrupted by sonication (Branson Sonifier
250) at 60% duty cycle until clarified. The cell lysate was
spun at 26,000g for 60 min in a SS34 rotor (Sorvall). The
supernatant was then passed through a 0.8-μm filter
before being applied to a 5 mL Ni-NTA column (Qiagen).
Once loaded onto the column, it was washed with column
binding buffer increased to 30 mM imidazole. The protein
was eluted using an ÄKTA Prime Plus FPLC (GE
Healthcare) with 100 mL of buffer containing imidazole
increased linearly to 250 mM. Fractions containing the
desired His6-SUMO-Tau353-408 were identified by 15%
SDS-PAGE gels and pooled.
The His6-SUMO tag was removed using the catalytic
domain of the Saccharomyces cerevisiae SUMO hydro-
lase Ulp1. Cleavage was performed overnight at RT using
5 μg/mL Ulp1 while also dialyzing the protein sample
against 20 mM NaH2PO4 and 150 mM NaCl, pH 7.0. The
resulting cTau353-408, expressed in the presence of
mutOGT, was then concentrated and loaded into a
10 × 250 mm semi-preparative C18 reversed phase HPLC
column (Higgins Analytical, Inc.) and subsequently eluted
using a 0–60%CH3CNgradient (0.1%TFA) at 1 mL/min over
80 min. Fractions (1 mL) were collected with a Gilson FC205
fraction collector, and those containing pure cTau353-408
were pooled and lyophilized. The ogTau353-408 and
cTau353-408 mixture, expressed in the presence of
wtOGT, was loaded into a 9.4 × 250 mm semi-preparative
C4 column (Agilent) and separated using a 22–27% CH3CN
gradient (0.1% TFA) over 100 min at 1 mL/min. The resulting
fractionswereanalyzedwithmatrix-assisted laser desorption/
ionization time-of-flight mass spectrometry. Samples most
enriched in ogTau353-408 were pooled and lyophilized. The
same HPLC purification step was repeated to prepare
EogTau353-408 (~88% modified and ~12% unmodified).
All Tau353-408 samples were resuspended in 10 mM
NaH2PO4 (pH 6.0), 0.016% protease stock inhibitor tablet
(Roche), and 10% D2O.
Theconcentrationsof the cTau353-408andogTau353-408
sampleswere determined quantitatively through the use of a
bicinchoninic acid assay (Thermo Scientific) using BSA as a
standard and spectrophotometrically using a NanoDrop
200c absorbance spectrophotometer (Thermo Scientific)
with a predicted molar absorptivity ε280 of 1490 M
−1 cm−1.
The final concentration for each Tau353-408 sample was
taken as the average of these two measurements.Mass spectrometry of Tau441
Samples were analyzed using an Agilent 6210 LC/MS
equipped with an electrospray ionization source (3500 V)
and a ZORBAX 300SB-C8 column housed in an Agilent
1100 series HPLC. Proteins (in 20 mM sodium phosphate
buffer, pH 7) were loaded onto a pre-equilibrated column
using 2% CH3CN containing 0.1% formic acid for 1 minand then eluted using a linear gradient of 2–60% CH3CN
containing 0.1% formic acid over 12 min. cTau441wt and
ogTau441wt eluted at 6.26 and 6.17 min. Extracted total
ion chromatograms were deconvoluted using MassHunter
workstation software (Agilent) to identify proteins ranging
in mass from 46,000 to 49,000 Da. For calculation of the
O-GlcNAc stoichiometry on ogTau441wt, the integration
values for the area of each of the O-GlcNAc-modified
peaks were added and divided by the integration values of
all the peaks attributed to tau.Tubulin polymerization assay
Bovine brain tubulin (N99% purity) was obtained from
Cytoskeleton, Inc. (Denver, CO, USA). Tubulin polymer-
ization assays were carried out using 18 μM tubulin, 3 μM
Tau441, 2.5 mM GTP, 1 mM dithiothreitol (DTT), 1 mM
ethylene glycol bis(β-aminoethyl ether) N,N′-tetraacetic
acid, and 2 mM MgCl2 in 80 mM Pipes, pH 6.9. Tubulin
polymerization was monitored by light scattering at
340 nm using a SpectraMax 340 (Molecular Devices).Immunoblotting
Samples were electrophoresed through 12% SDS-PAGE
and transferred to nitrocellulose membranes (Bio-Rad).
Membranes were then blocked for 1 h at RT using 2% BSA
in PBS (phosphate-buffered saline) containing 0.1%
Tween-20 (Sigma) (PBS-T) and subsequently probed
overnight at 4 ºC with the appropriate primary antibody in
PBS-T plus 2%BSA. Membranes were extensively washed
with PBS-T, blocked again for 30 min using 2% BSA in
PBS-T at RT, and probed for 1 h at RT with the appropriate
HRP (horseradish peroxidase)-conjugated secondary anti-
body in PBS-T plus 2% BSA. Finally, the membranes were
washed extensively with PBS-T and then treated with
SuperSignal West Pico Chemiluminescence substrate
(Pierce) and exposed to CL-XPosure Film (Pierce) for
visualization of immunoreactive protein bands.Total tau ELISA
We coated 2 μg/mL of the total tau capture antibody
BT-2 (Pierce), which recognizes amino acids 194–198 of
tau (a region not modified by O-GlcNAc), onto wells of
Maxisorp ELISA plates (Nunc) in 100 mM sodium bicarbon-
ate/carbonate buffer, pH 9.5, overnight at 4 °Cwith shaking.
On the next day, the capture antibody was aspirated and the
plates were blocked with 5% BSA in PBS for 1 h at RT.
cTau441wt and ogTau441wt samples, serially 2-fold diluted
from 10,000 pg/mL to 10 pg/mL with 1% BSA in PBS, were
applied to the plate and incubated for 2 h at RT. After
washing five times with PBS-T2 (0.05% Tween), we applied
0.5 μg/mLof a biotinylated total tauTau-5detection antibody
(Thermo) in 1% BSA in PBS to the plate. This antibody
recognizes amino acids 218–225 of tau (a region not
modified by O-GlcNAc). Five more washes with PBS-T2
were carried out, followed by incubation with 1:10,000
dilution of Streptavidin-HRP (Pierce) in 1% BSA in PBS.
Finally, the plate waswashed seven timeswith PBS-T2, and
the ELISA was developed using 3,3′,5,5′-tetramethylbenzi-
dine as the substrate for HRP. After quenching by 2 M
H2SO4, we read the signal at 450 nm using a SpectraMax
340 plate reader (Molecular Devices).Tau441 aggregation in vitro monitored by ThS
Tau aggregation experiments were performed using
10 μM Tau441 protein (for EogTau441, it was 5 μM tau
concentration), 1 mM DTT, 1 mM PMSF, and 0.01 mg/mL
thioflavin (ThS) in 20 mM sodium phosphate buffer, pH 7.
Reactions were initiated by the addition of 10 μM heparin
(5600–6400 Da average molecular weight; International
Laboratory, USA) to the reaction mixtures contained in
wells of a 96-well fluorescence microplate (Nunc) or a
384-well fluorescence microplate (Corning). The aggrega-
tion process was followed by reading the microplate (at the
indicated times) in a Molecular Devices Fmax spectroflu-
orometer using an excitation filter of 440 nm and an
emission filter of 520 nm (for 96-well plates) and using a
BioTek Synergy4 microplate reading (for 384-well plates).
Between readings, the microplate was incubated at 37 ºC
in a sealed humidified box to prevent evaporation of
water from the aggregation reactions and fresh 1 mM DTT
was added every 24 h from a 100 mM stock so as to not
significantly dilute the assays. Data were corrected by
subtraction of control samples, which contained all of the
reaction mixture components except for the tau protein.
Experiments were performed in at least triplicate, and data
are presented as the ThS fluorescence average ± standard
error of the mean. For Tau441wt progress curves, data were
fit to either a Gompertz growth function or a one-phase
exponential association model using GraphPad Prism 5.03.
The Gompertz growth model was used as described
previously [42,63]:
y ¼ ym e−e
− t−t ið Þkapp
where y is the fluorescence value measured at time t, ym
is the plateau fluorescence value, ti is the inflection point
when fluorescence is changing most rapidly, and kapp
is proportional to the rate of polymerization. The lag time
is defined as ti − 1/kapp.
Tau353-408 aggregation in vitro monitored by ThS
Experiments were performed and analyzed as described
above, except that samples contained 50 μM Tau353-408
and 12.5 μMheparin in a total of 50 μL. Sampleswere placed
in a black flat-bottom 386-well plate (Grenier), sealed with
optically clear crystallography tape (Hampton Research) to
limit evaporation, and incubatedat 37 °C.The fluorescenceof
samples was measured every 15 min using a Varioskan
Flash fluorimeter (Thermo Scientific).Tau441 aggregation in vitro monitored by filter-trap
assay
Tau aggregation studies were performed using 10 μM
Tau441 protein, 1 mM DTT, and 1 mM PMSF in 20 mM
sodium phosphate buffer, pH 7. Reactions were initiated
by the addition of 10 μM heparin to the reaction mixtures.
For the time course data, aliquots were removed from each
replicate at the indicated time, fixed with 2% glutaralde-hyde, quenched with 50 mM Tris, pH 7.6, and then flash
frozen and stored at −80 °C until all of the time points were
collected. After 5 days, all of the samples were diluted
20-fold in PBS containing 2% SDS and filtered through a
0.45-μm nitrocellulose membrane (Bio-Rad) that was
pre-equilibrated using 2% SDS in PBS. Each well was
washed four times using PBS containing 2% SDS, and the
membrane was then removed from the apparatus and
blocked using PBS containing 1% BSA for 1 h at RT. HT7
primary antibody (0.5 μg/mL) in PBS containing 1% BSA
was applied, and the solution was incubated for 1 h at RT.
The membrane was then washed with PBS-T three times
over 15 min with continual rocking, blocked for 15 min
using 1% BSA in PBS, and incubated with 1:1000 IRDye
680LT Goat anti-Mouse IgG (H + L) (Li-Cor) in PBS
containing 1% BSA for 1 h at RT in the dark. Following
three 15-min washes using PBS-T, we imaged the
membrane using the Li-Cor Odyssey and quantified
immunoreactivity using Li-Cor Image Studio software.
FRET analysis
The tau FRET experiments were carried out by following
as closely as possible the previously published protocol
[23,46]. TheC291Smutationwas introduced into theTau441
gene contained in the pET28a plasmid using the following
primers: 5′-GCAACGTCCAGTCCAAGTCTGGCTCAAAG
GATAATATC-3′ and 5′-GATATTATCCTTTGAGCCA
GACTTGGACTGGACGTTGC-3′. The V432W mutation
was introduced using the following primers: 5′-CCACGC
TAGCTGACGAGTGGTCTGCCTCCCTGGCCAAG-3′ and
CTTGGCCAGGGAGGCAGACCACTCGTCAGC
TAGCGTGG-3′. Both of these mutations were introduced
using the Stratagene QuikChange site-directed mutagene-
sis kit. The plasmids encoding the double mutant were
co-transformed with those encoding mutOGT or wtOGT to
produce cTau441C291S/V432W or ogTau441C291S/V432W, re-
spectively. The resulting co-transformants were cultured in
LB media to an OD600 of 0.6–0.8, induced using 0.5 mM
IPTG for 20 h, and purified by Ni-NTA chromatography, as
described above. The resulting Tau441C291S/V432W and
ogTau441C291S/V432W samples were reduced using a
5-fold molar excess of TCEP at 37 °C for 15 min. The
samples were then incubated for 2 h at RT with a 10-fold
molar excess of 1,5-IAEDANS (Invitrogen) dissolved in
DMF such that the solution concentration contained a final
DMF concentration of 1% (v/v). Following desalting over
a PD-10 desalting column (GE Healthcare) to remove
excess unreacted 1,5-IAEDANS and the DMF, the
cTau441*C291S/V432W and ogTau441*C291S/V432W samples
were HPLC purified, as described above. Samples were
dissolved in 10 mM sodium phosphate buffer, pH 7, and
protein concentrationswere determined by two independent
methods: the Bio-Rad DC assay and confirmed by relative
spectrophotometric analysis of the HPLC elution profile
monitoring absorbance at 220 nm. Fractional labeling
was determined from the HPLC elution profile using the
absorbance at 336 nm to quantitate the 1,5-IAEDANS
(ε336 = 5700 M
−1 cm−1) relative to the protein concentra-
tion. The fractional labeling of tau with 1,5-IAEDANS was
1.0 for the cTau441*C291S/V432W and was 0.8 for the
ogTau441*C291S/V432W. The FRET efficiencies and the
resulting intermolecular distances were measured and
calculated, respectively, as previously described [23,46].
NMR spectroscopy
NMR data were recorded using an 850 MHz Bruker
Avance III spectrometer with samples maintained at 15 ºC
in 10 mM sodium phosphate buffer, pH 6.0, with 10% lock
D2O. These conditions were found to be optimal for
minimizing signal loss due to amide hydrogen exchange
while yielding good quality spectra under near neutral pH
conditions. Spectra were processed and analyzed using
NMRPipe [64] and Sparky [65], respectively. Main-chain
chemical shifts were obtained using CBCA(CO)NH,
HNCACB, HNCO, (H)CC(CO)TOCSY-NH, NNH, and
HNHA experiments [66,67]. Amide heteronuclear
15N-NOE spectra recorded with or without 5 s of 1H
saturation and a total recycle delay of 5 s [68]. The
resulting data were fit using the nlinLS routine of NMRPipe
[64], and errors were estimated from repeat measure-
ments. Main-chain 3JHN-Hα were extracted from HNHA
spectra [69]. Interproton NOE measurements were carried
out using HNH- and NNH-NOE-HSQC (τmix = 200 ms)
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